Caris Life Sciences (CAI) Payables (2024 - 2026)

Caris Life Sciences has reported Payables for 3 years, with the latest figure at $86.0 million in Q2 2026.

• On a quarterly basis, Payables rose 199.31% year-over-year to $86.0 million in Q2 2026; TTM through Jun 2026 was $86.0 million, a 199.31% increase from a year earlier, with the FY2025 full-year figure at $39.2 million, up 41.07% from the prior year.
• Payables was $86.0 million for Q2 2026 at Caris Life Sciences, up from $69.8 million in the prior quarter.
• The five-year high for Payables was $86.0 million in Q2 2026, with the low at $27.8 million in Q4 2024.
• Average Payables over 3 years is $46.8 million, with a median of $34.1 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Payables surged 41.07% in 2025, then surged 199.31% in 2026.
• Over 3 years, Payables stood at $27.8 million in 2024, then soared by 41.07% to $39.2 million in 2025, then soared by 119.32% to $86.0 million in 2026.
• The last three Payables figures came in at $86.0 million (Q2 2026), $69.8 million (Q1 2026), and $39.2 million (Q4 2025), per Business Quant data.